Type 1 Diabetes Treatment Market Report 2024 (Global Edition)

Global Type 1 Diabetes Treatment Market Report 2024 Market Size Split by Product (Rapid-Acting Insulin, Short-Acting Insulin, Medium-Acting Insulin, Long-Acting Insulin, Others), by End User (Hospital...

Type 1 Diabetes Treatment Market Report Description

We have various report editions of Type 1 Diabetes Treatment Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Type 1 Diabetes Treatment Market

The Type 1 Diabetes Treatment Market exhibits a competitive landscape characterized by ongoing innovation, strategic collaborations, and robust R&D efforts. Companies vie for market share through product differentiation, pricing strategies, and expansion into emerging markets, driving competition and fostering advancements in treatment modalities.

Top Companies Market Share in Type 1 Diabetes Treatment Industry: (In no particular order of Rank)

• Abbott Laboratories
• Bayer AG
• Eli Lilly and Company
• GlaxoSmithKline
• Johnson & Johnson Ltd
• Merck & Co
• Pfizer Inc
• Takeda Pharmaceutical
• AstraZeneca PLC
• XOMA Corp
• Others
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Type 1 Diabetes Treatment Market

Which Region Will Dominate the Type 1 Diabetes Treatment Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue due to several factors. Firstly, the region boasts advanced healthcare infrastructure and high levels of awareness about diabetes management, leading to increased diagnosis and treatment rates. Moreover, a large diabetic population, coupled with favourable reimbursement policies and robust R&D activities, drives market growth. Additionally, the presence of key market players and continuous technological advancements contribute to the dominance of North America in revenue generation within the Type 1 diabetes treatment market.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is the fastest-growing region fuelled by various factors. Rising disposable incomes, urbanization, and changing lifestyles contribute to an increasing prevalence of type 1 diabetes, expanding the market. Moreover, improving healthcare infrastructure, government initiatives to combat diabetes, and growing awareness drive demand for treatment options. Additionally, the region benefits from a large underserved population, offering significant growth opportunities for market expansion. Furthermore, collaborations between international pharmaceutical companies and local stakeholders facilitate the introduction of innovative therapies, accelerating market growth in Asia-Pacific.

The current report Scope analyzes Type 1 Diabetes Treatment Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Type 1 Diabetes Treatment Market

According to Cognitive Market Research, the global type 1 diabetes treatment market size was estimated at USD 8154.2 Million out of which North America held the major market of around 40% of the global revenue with a market size of USD 3261.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031. Sales of type 1 diabetes treatment in North America are poised for growth due to the region's robust healthcare infrastructure and increasing prevalence of the condition. Rising adoption of advanced insulin delivery systems and continuous glucose monitoring technologies, alongside favourable reimbursement policies, drives market expansion. Moreover, the emphasis on preventive care and early intervention strategies by healthcare providers contributes to higher diagnosis rates and treatment initiation. In particular, the rapid-acting insulin segment is expected to thrive, supported by technological advancements and patient preference for convenient dosing options in this region.

Country Analysis

• According to Cognitive Market Research, The United States type 1 diabetes treatment market had a market share of USD 2573.47 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. Sales of type 1 diabetes treatment will increase in the U.S. due to a large diabetic population, advanced healthcare infrastructure, and increasing adoption of insulin pumps and continuous glucose monitoring systems.
• Canada type 1 diabetes treatment market had a market share of USD 391.40 million in 2024 and is projected to grow at a CAGR of 7.0% during the forecast period. In Canada, sales of type 1 diabetes treatment will rise owing to government initiatives promoting diabetes management, growing awareness about the condition, and advancements in insulin delivery technologies.
• Mexico type 1 diabetes treatment market had a market share of USD 296.81 million in 2024 and is projected to grow at a CAGR of 6.7% during the forecast period.

Europe Type 1 Diabetes Treatment Market

According to Cognitive Market Research, with a market value of USD 8154.2 million in 2024 and projected to expand at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031. Europe accounted for a share of around 30% of the global market size of USD 2446.26 million. The type 1 diabetes treatment market in Europe is forecasted to witness significant growth owing to increasing awareness about diabetes management and rising healthcare expenditure. Technological innovations in insulin delivery systems and glucose monitoring devices drive market penetration, especially in countries with high diabetes prevalence rates. Additionally, collaborative efforts between pharmaceutical companies and healthcare providers to develop personalized treatment regimens foster market expansion. Long-acting insulin segment is expected to dominate, driven by its efficacy in providing basal insulin coverage and reducing the risk of hypoglycaemia, particularly in the European market.

• The United Kingdom type 1 diabetes treatment market had a market share of USD 410.97 million in 2024 and is projected to grow at a CAGR of 7.3% during the forecast period. The UK will see increased sales of type 1 diabetes treatment due to its comprehensive healthcare system, emphasis on preventive care, and rising demand for advanced insulin delivery systems.
• France type 1 diabetes treatment market had a market share of USD 225.06 million in 2024 and is projected to grow at a CAGR of 5.7% during the forecast period.
• Germany type 1 diabetes treatment market had a market share of USD 484.36 million in 2024 and is projected to grow at a CAGR of 6.7% during the forecast period. Sales of type 1 diabetes treatment in Germany will increase driven by a high prevalence of diabetes, robust healthcare infrastructure, and strong R&D activities focusing on innovative treatment modalities.
• Italy type 1 diabetes treatment market had a market share of USD 210.38 million in 2024 and is projected to grow at a CAGR of 5.9% during the forecast period.
• Russia type 1 diabetes treatment market had a market share of USD 379.17 million in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period.
• Spain type 1 diabetes treatment market had a market share of USD 200.59 million in 2024 and is projected to grow at a CAGR of 5.6% during the forecast period.
• Luxembourg type 1 diabetes treatment market had a market share of USD 75.83 million in 2024 and is projected to grow at a CAGR of 6.6% during the forecast period.
• Portugal type 1 diabetes treatment market had a market share of USD 51.37 million in 2024 and is projected to grow at a CAGR of 6.3% during the forecast period.
• Greece type 1 diabetes treatment market had a market share of USD 29.36 million in 2024 and is projected to grow at a CAGR of 6.8% during the forecast period.
• Rest of Europe type 1 diabetes treatment market had a market share of USD 379.17 million in 2024 and is projected to grow at a CAGR of 5.2% during the forecast period.

 

Asia Pacific Type 1 Diabetes Treatment Market

According to Cognitive Market Research, the global type 1 diabetes treatment market size was estimated at USD 8154.2 Million out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 1875.47 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031. In the Asia Pacific region, sales of type 1 diabetes treatment are expected to surge due to factors such as rapid urbanization, changing lifestyles, and increasing disposable incomes. Growing healthcare infrastructure and rising awareness about diabetes management contribute to higher diagnosis rates and treatment uptake. Furthermore, the adoption of telemedicine and digital health solutions enhances patient access to care, particularly in remote areas. The rapid growth of the medium-acting insulin segment is anticipated, driven by its affordability and suitability for diverse patient populations across Asia Pacific.

• According to Cognitive Market Research, China type 1 diabetes treatment market had a market share of USD 843.96 million in 2024 and is projected to grow at a CAGR of 9.5% during the forecast period. In China, sales of type 1 diabetes treatment will surge due to rapid urbanization, increasing disposable incomes, and government initiatives to improve healthcare access and affordability for chronic disease management.
• Japan type 1 diabetes treatment market had a market share of USD 258.81 million in 2024 and is projected to grow at a CAGR of 8.5% during the forecast period.
• India type 1 diabetes treatment market had a market share of USD 225.06 million in 2024 and is projected to grow at a CAGR of 11.8% during the forecast period. India will witness a boost in sales of type 1 diabetes treatment due to the rising prevalence of diabetes, expanding middle-class population, and increasing adoption of digital health solutions for remote patient monitoring.
• South Korea type 1 diabetes treatment market had a market share of USD 187.55 million in 2024 and is projected to grow at a CAGR of 9.1% during the forecast period.
• Australia type 1 diabetes treatment market had a market share of USD 97.52 million in 2024 and is projected to grow at a CAGR of 9.7% during the forecast period.
• South East Asia type 1 diabetes treatment market had a market share of USD 129.41 million in 2024 and is projected to grow at a CAGR of 11.0% during the forecast period.
• Rest of Asia Pacific type 1 diabetes treatment market had a market share of USD 133.16 million in 2024 and is projected to grow at a CAGR of 9.8% during the forecast period.

 

South America Type 1 Diabetes Treatment Market

According to Cognitive Market Research, the global type 1 diabetes treatment market size was estimated at USD 8154.2 Million out of which Latin America market of around 5% of the global revenue with a market size of USD 407.71 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2031. Sales of type 1 diabetes treatment in Latin America are projected to increase due to improving healthcare infrastructure and rising healthcare expenditure. Government initiatives aimed at diabetes prevention and management drive awareness and diagnosis rates, contributing to market growth. Additionally, increasing adoption of insulin pumps and continuous glucose monitoring systems enhances treatment efficacy and patient outcomes. The short-acting insulin segment is expected to lead in this region, fuelled by its versatility in managing postprandial glucose levels and flexibility in dosing adjustments to accommodate dietary variations common in Latin American diets.

• According to Cognitive Market Research, Brazil type 1 diabetes treatment market had a market share of USD 174.50 million in 2024 and is projected to grow at a CAGR of 8.0% during the forecast period. Sales of type 1 diabetes treatment in Brazil will increase owing to improving healthcare infrastructure, rising awareness about diabetes management, and growing demand for insulin analogy and continuous glucose monitoring devices.
• Argentina type 1 diabetes treatment market had a market share of USD 68.50 million in 2024 and is projected to grow at a CAGR of 8.3% during the forecast period. In Argentina, sales of type 1 diabetes treatment will rise due to government efforts to combat diabetes, increasing healthcare expenditure, and growing availability of advanced insulin delivery systems and monitoring devices.
• Colombia type 1 diabetes treatment market had a market share of USD 36.29 million in 2024 and is projected to grow at a CAGR of 7.2% during the forecast period.
• Peru type 1 diabetes treatment market had a market share of USD 33.43 million in 2024 and is projected to grow at a CAGR of 7.6% during the forecast period.
• Chile type 1 diabetes treatment market had a market share of USD 29.36 million in 2024 and is projected to grow at a CAGR of 7.7% during the forecast period.
• Rest of Latin America type 1 diabetes treatment market had a market share of USD 65.64 million in 2024 and is projected to grow at a CAGR of 6.5% during the forecast period.

 

Middle East and Africa Type 1 Diabetes Treatment Market

According to Cognitive Market Research, the global type 1 diabetes treatment market size was estimated at USD 8154.2 Million out of which Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 163.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2031. The MEA region's type 1 diabetes treatment market is set to expand due to improving access to healthcare services and increasing diabetes prevalence rates. Rising investments in healthcare infrastructure and government initiatives to combat chronic diseases drive market growth. Additionally, the adoption of telemedicine and mobile health solutions improves diabetes management, particularly in underserved areas. The long-acting insulin segment is anticipated to dominate in this region, supported by its efficacy in providing sustained basal insulin coverage, essential for managing diabetes in resource-constrained settings like the Middle East and Africa.

• According to Cognitive Market Research, GCC Countries type 1 diabetes treatment market had a market share of USD 69.80 million in 2024 and is projected to grow at a CAGR of 8.5% during the forecast period. Sales of type 1 diabetes treatment in GCC Countries will increase driven by high diabetes prevalence rates, government investments in healthcare infrastructure, and rising adoption of telemedicine and digital health solutions.
• Egypt type 1 diabetes treatment market had a market share of USD 17.12 million in 2024 and is projected to grow at a CAGR of 8.0% during the forecast period.
• South Africa type 1 diabetes treatment market had a market share of USD 25.77 million in 2024 and is projected to grow at a CAGR of 8.7% during the forecast period. South Africa will see increased sales of type 1 diabetes treatment due to improving access to healthcare services, rising diabetes awareness, and the adoption of mobile health technologies for diabetes management.
• Turkey type 1 diabetes treatment market had a market share of USD 14.03 million in 2024 and is projected to grow at a CAGR of 7.2% during the forecast period.
• Nigeria type 1 diabetes treatment market had a market share of USD 17.12 million in 2024 and is projected to grow at a CAGR of 6.8% during the forecast period.
• Rest of MEA type 1 diabetes treatment market had a market share of USD 19.24 million in 2024 and is projected to grow at a CAGR of 6.7% during the forecast period.

 

Type 1 Diabetes Treatment Market Analysis

Type 1 Diabetes Treatment Product Segment Analysis

According to Cognitive Market Research, rapid-acting insulin held the major market share over the forecast period due to its crucial role in managing postprandial glucose levels effectively. Increased adoption stems from its rapid onset of action and convenience, particularly for patients requiring precise mealtime dosing. Moreover, advancements in delivery systems enhance patient adherence and comfort, further driving sales. Additionally, the rising prevalence of type 1 diabetes and the growing demand for insulin analogy contribute to the sustained dominance of rapid-acting insulin in the market.

Long-acting insulin is the fastest-growing category over the forecast period due to its pivotal role in providing basal insulin coverage. Continuous innovations result in extended duration formulations, reducing the frequency of injections and enhancing patient convenience. Moreover, the increasing adoption of long-acting analogy over traditional insulins propels segment growth. Additionally, the rising emphasis on glycaemic control and the expansion of treatment options in emerging markets contribute to the accelerated sales of long-acting insulin.

• Rapid-Acting Insulin
• Short-Acting Insulin
• Medium-Acting Insulin
• Long-Acting Insulin
• Others

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Type 1 Diabetes Treatment Industry. Request a Free Sample PDF!

Type 1 Diabetes Treatment End User Segment Analysis

According to Cognitive Market Research, hospitals and clinics hold a prominent market share due to their role as primary points of care for type 1 diabetes patients. Their widespread availability and comprehensive services attract a large patient pool. Additionally, these facilities often serve as referral centres for complex cases, further bolstering their market share. Moreover, advancements in diabetes management technologies integrated into hospital systems enhance treatment outcomes, driving sales.

Specialty centres is the fastest-growing category over the forecast period due to their specialized expertise and focus on diabetes care. Patients increasingly seek specialized treatment options and personalized care, leading to higher demand for services provided by specialty centres. Furthermore, collaborations with pharmaceutical companies and research institutions facilitate access to cutting-edge therapies and clinical trials, further driving segment growth. Additionally, the rising prevalence of diabetes-related complications necessitates specialized care, contributing to the accelerated sales of specialty centre services.

• Hospitals and Clinics
• Specialty Centers
• Others

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion